The opening of an office in Milan will enable PharmaLex to provide specialist support to the third largest pharmaceutical market in Europe
Frankfurt, Germany / Milan, Italy, February 20th 2018: As of February 5th, 2018, PharmaLex Group, one of the largest providers for Development Consulting, Regulatory Affairs, Quality Management & Compliance and Pharmacovigilance, Epidemiology & Risk Management worldwide, has expanded its operations to Italy, with the opening of an office in Milan.
The Milan office will be the base for PharmaLex Italy which will be headed by Fulvia Feltrin. Fulvia will be working to build PharmaLex’s local presence and establish a new legal entity. Fulvia joins PharmaLex from a leading regulatory affairs provider, where she served as General Manager, Italy. With a professional career spanning more than 25 years within the pharmaceutical industry, Fulvia has primarily worked in Regulatory Affairs holding roles of increasing responsibility. She has managed and supported regulatory affairs teams, provided strategic support for clients, and contributed to the growth and development of the business. A highly experienced leader, Fulvia has proven expertise in managing multisite and multidisciplinary teams, handling complex and differentiated projects, and achieving the company’s strategic goals through effective management. She has a master’s degree in Pharmaceutical Chemistry and Technology from the University of Milan.
“I care about delivering high quality services in the fastest and most efficient way, and I like to operate in an environment where people work with passion, commitment and enthusiasm. PharmaLex completely supports this approach. With the establishment of the new Italian office, we will be able to offer clients a complete, high-standard service portfolio, promoting a wide range of services and, for multinational businesses, extended market coverage. Customer care and advisors speaking the local language complete the support offered to clients”, explained Fulvia Feltrin, Country Manager Italy.
“Italy represents the third largest European pharmaceutical market, after Germany and France; therefore the establishment of a local office is an important milestone in the European presence of PharmaLex”, explained Dr Thomas Dobmeyer, CEO PharmaLex. “What Italian customers need, are high standard services in line with all EU regulations and requirements, plus a local presence to work in strict collaboration establishing strong sense of partnership”, added Dr Tilo Netzer, CEO PharmaLex.
The PharmaLex Group now has over 700 employees, with 32 offices in 16 countries and more than 600 satisfied clients worldwide.
About PharmaLex <Confidence beyond compliance>:
Development Consulting, Regulatory Affairs, Quality Management & Compliance as well as Pharmacovigilance – are our core service areas. Whether you are looking for maintenance activities covering entire portfolios or are interested in bench-to-market guidance during product development and beyond, our worldwide teams are available when and where you need them. Our working models can be tailored to fit client needs to consistently deliver milestone achievements and exceed expectations. Our extensive experience covers all major therapeutic areas and most product categories beyond the traditional medicinal products, including advanced therapy medicinal products, orphan drugs, biosimilars and medical devices.